2. Signaling Pathways
  3. Neuronal Signaling
    Protein Tyrosine Kinase/RTK
  4. Trk Receptor

Trk Receptor

Tropomyosin related kinase receptor

Trk Receptor

Related Products

PDF 0.95 MB

Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).

TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.

The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.

Trk Receptor Isoform Specific Products:

Trk Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990473
    Anti-MUSK Antibody
    		Inhibitor
    Anti-MUSK Antibody is a humanized antibody expressed in CHO that targets MUSK. The Anti-MUSK Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 143.86 kDa. For the isotype control of Anti-MUSK Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
    Anti-MUSK Antibody
  • HY-12678R
    Entrectinib (Standard)
    		Inhibitor
    Entrectinib (Standard) is the analytical standard of Entrectinib. This product is intended for research and analytical applications. Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice.
    Entrectinib (Standard)
  • HY-101977B
    (3aR)-Selitrectinib
    		Inhibitor
    (3aR)-Selitrectinib ((3aR)-LOXO-195) is an isform of Selitrectinib (HY-101977), which is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively.
    (3aR)-Selitrectinib
  • HY-164517
    ONO-7579
    		Inhibitor
    ONO-7579 is an orally active TRKA inhibitor that suppresses tumor growth by inhibiting the phosphorylation of TRKA. In colorectal cancer cells KM12, its EC50 is 17.6 ng/g (meaning that when each gram of tumor tissue contains 17.6 ng of ONO-7579, the activity of phosphorylated TRKA in the tumor is inhibited by 50%). ONO-7579 can be used in cancer research.
    ONO-7579
  • HY-169514
    TrkA-IN-8
    		Inhibitor
    TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 exhibits concentration-dependent inhibition of cell proliferation in lung cancer cell lines. RTKs-IN-1 holds potential for research in non-small cell lung cancer .
    TrkA-IN-8
  • HY-12866R
    Larotrectinib (Standard)
    		Inhibitor
    Larotrectinib (Standard) is the analytical standard of Larotrectinib. This product is intended for research and analytical applications. Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
    Larotrectinib (Standard)
  • HY-118271
    GNF-8625
    		Inhibitor
    GNF-8625 is a broad-spectrum TRK inhibitor that can combine with Thalidomide to form a PROTAC degrader. The IC50 of GNF-8625 for inhibiting TRKA, TRKB, and TRKC are 0.8 nM, 22 nM, and 5.4 nM, respectively.
    GNF-8625
  • HY-177082
    Eratrectinib
    		Inhibitor
    Eratrectinib (Example 1) is a Trk inhibitor. Eratrectinib can be studied in research for tropomyosin receptor kinase-related diseases and cancers.
    Eratrectinib
  • HY-164461
    AZD6918
    		Inhibitor
    AZD6918 is an orally active and selective Trk tyrosine kinase inhibitor. AZD6918 induces cell death as a single agent and attenuates BDNF/TrkB-induced protection from Etoposide (HY-13629) in vitro. AZD6918 can be used for the research of neuroblastoma.
    AZD6918
  • HY-164483
    HS-345
    		Inhibitor
    HS-345 is a TrkA/Ak inhibitor with significant anti-pancreatic cancer effects. HS-345 inhibits the growth and proliferation of pancreatic cancer cells by targeting the TrkA/Akt signaling pathway, while also inducing apoptosis. Additionally, HS-345 suppresses blood vessel formation by decreasing the expression of HIF-1α and VEGF. HS-345 holds promise for research in pancreatic cancer.
    HS-345
  • HY-P990474
    Anti-NGF/bNGF Antibody
    		Inhibitor 99.65%
    Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
    Anti-NGF/bNGF Antibody
  • HY-12497R
    ANA-12 (Standard)
    		Antagonist
    ANA-12 (Standard) is the analytical standard of ANA-12. This product is intended for research and analytical applications. ANA-12 is a potent and selective TrkB antagonist with IC50s of 45.6 nM and 41.1 μM for the high and low affinity sites, respectively.
    ANA-12 (Standard)
  • HY-171450
    VMD-928
    		Inhibitor
    VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma.
    VMD-928
  • HY-12866AR
    Larotrectinib sulfate (Standard)
    		Inhibitor
    Larotrectinib sulfate (Standard) is the analytical standard of Larotrectinib sulfate. This product is intended for research and analytical applications. Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
    Larotrectinib sulfate (Standard)
  • HY-101977R
    Selitrectinib (Standard)
    		Inhibitor
    Selitrectinib (Standard) is the analytical standard of Selitrectinib. This product is intended for research and analytical applications. Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively.
    Selitrectinib (Standard)
  • HY-W013372R
    7,8-Dihydroxyflavone (Standard)
    		Agonist
    7,8-Dihydroxyflavone is a potent and selective TrkB agonist that mimics the physiological actions of Brain-derived neurotrophic factor (BDNF). Displays therapeutic efficacy toward various neurological diseases.
    7,8-Dihydroxyflavone (Standard)
  • HY-110255B
    AZD-2066 hydrochloride
    		Activator
    AZD-2066 hydrochloride is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 hydrochloride activates the BDNF/trkB signaling pathway. AZD 2066 hydrochloride can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease.
    AZD-2066 hydrochloride
  • HY-167836
    BNN-20
    		Activator
    BNN-20 is a synthetic microneurotrophin that mimics brain-derived neurotrophic factor (BDNF) and exhibits area-specific pleiotropic neuroprotective and pro-neurogenic effects. BNN-20 can be utilized in research related to Parkinson's disease.
    BNN-20
Cat. No. Product Name / Synonyms Application Reactivity
Trk Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.